Important reductions in cardiovascular mortality that have occurred over the past three decades in most industrialised regions have not been accompanied by a decline in mortality or admissions to hospital for cardiac failure. ' Congestive heart failure (CHF) continues to be a lethal end stage of cardiovascular disease caused by hypertension, coronary disease, valve deformity, diabetes, and cardiomyopathy. As premature deaths from these conditions are avoided by means of more effective medical and surgical interventions, the prevalence of cardiac failure can be expected to rise because the predisposing conditions are palliated, not cured. Increased size of the elderly population also increases the prevalence of heart failure.
Size of the problem: prevalence and incidence Based on the National Health and Nutrition Survey, it has been estimated that from one to two million people in the United States under the age of 75, excluding people in nursing homes and other residential institutions, have CHF.' When people of > 75 and those in institutions are included, the range is closer to two to three million people of whom about one half are > 65.' 2 The mild end of the range is based on self reporting and the severe end is based on a clinical score. Prevalence rises with age from 1% of the population aged 25 to 54 to 4-5% at 65-74.2 It is probably nearer to 10% in those >75. National statistics based on admissions to hospital and visits to clinics also indicate a high incidence of heart failure in the United States.' 3 There were 722 000 hospital discharges in 1990 with cardiac fail- 1980 1982 1984 1986 1988 1990 Year Figure 1 Rates of admission to hospitalfor heart failure in the (table 2) . A substantial proportion, however, have coexistent hypertension. Coronary disease, hypertension, and diabetes singly or in combination, predominate as causes of heart failure. Some 87% of cases of cardiac failure in the general population are associated with either coronary disease or hypertension.8 Coronary disease and diabetes seem to be increasingly responsible for heart failure in recent years (table 3) . Hypertension and valvar heart disease are diminishing determinants.
Mortality
Overt heart failure is the terminal stage of cardiac disease that ensues when the myocardium has exhausted its reserve capacity and compensatory mech-anisms. Once overtly manifest, epidemiological surveillance indicates an ominous outlook for progression and survival, with a cardiac mortality four to eight times that of the general population of the same age. Sudden death, a prominent component of this mortality occurs over six years in 9% of men and 4% of women with symptomatic cardiac failure. The sudden death rate associated with heart failure is five times that of the general population of the same age (table 4) .
According to a tabulation of multiple causes of death by the National Center for Health Statistics, in 1988 1968 1970 1972 1974 1976 1978 1980 1982 1984 1986 1988 1990 Year The Framingham Study found that survival is adversely affected by age with a 27% increase in mortality per decade of advancing age in men and a 61 % increment in women. This has not been consistently noted in other studies.'2-19 The Framingham Study finding may be closer to the truth because of the longer follow up and complete inclusion of all types of heart failure from the time of onset. This seems to have enhanced the statistical power to show the adverse influence of age.
Framingham Study patients with heart failure from coronary heart disease had a better outlook than has been found in comparable patients in placebo groups of various medical intervention trials and some clinical series. '1-5 This is likely because the Framingham Study survival statistics were calculated from the actual time of diagnosis, in an unselected sample, including people who have been excluded from intervention trials because of advanced age, acute myocardial infarctions, and uncontrolled angina. On restricting the Framingham Study data analysis to patients who survived at least 90 days after the diagnosis of heart failure, the survival results more closely resemble those noted in intervention trials.8 20 Women with diabetes and electrocardio- Predisposing cardiovascular diseases, particularly in the elderly, greatly augment the risk of heart failure. Coronary disease confers a fourfold increase in risk of cardiac failure with rates higher after myocardial infarction, whether silent or overt, than after angina ( fig  6) . Congenital heart disease and acquired valve disease are also powerful risks for heart failure but carry a lower attributable risk because they are less prevalent. Hypertensive cardiovascular disease with left ventricular hypertrophy is a common and powerful predisposing cardiovascular condition. About 75% of cardiac failure is associated with hypertension with or without other associated cardiac conditions (table 2) .
About 18% of cardiac-failure is associated with left ventricular hypertrophy previously detected by electrocardiography.8 Echocardiography provides more reliable and sensitive indications of increase in left ventricular mass that is present in many asymptomatic patients with hypertension, coronary disease, valve disease, diabetes, or obesity. Both anatomical and electrocardiographic indications of left ventricular hypertrophy carry a high risk of cardiac failure (fig 7) .
Myocyte hypertrophy, loss of muscle cells, and interstitial fibrosis are common features of all aetiologies of heart failure including myocardial infarction, exposure to toxins, viral myocarditis, Chagas' disease, diabetes, and hypertension. Whatever the cause of myocardial dysfunction, people who have an altered ventricular geometry and function are at greater risk of developing heart failure. It is now possible by non-invasive tests to safely evaluate the structure and function of the heart before the onset of symptoms. Recent investigations have shown that treatment of asymptomatic patients with ventricular dysfunction can delay the onset of cardiac failure and prolong survival.22
Seeking out people with predisposing cardiovascular risk factors provides a means for earlier and more efficient prevention of cardiac failure. Hypertension, left ventricular hypertrophy, impaired glucose tolerance, dyslipidaemia, obesity, cigarette smoking (table  5) , and excessive alcohol intake are the chief modifiable risk factors now predisposing to cardiac failure. Elderly people are at especially high risk both because of a longer exposure to these risk factors and aging itself.
Hypertension is a main contributor to incidence of heart failure because it increases the risk of CHF threefold and is also highly prevalent in the general population (table 5) . Incidence of heart failure increases with the severity of hypertension whether predominantly systolic or diastolic in nature. Risk of CHF is substantial in people with isolated systolic hypertension. Comparing the impact of the various components of blood pressure suggests that in women systolic pressure is most predictive and in men pulse pressure rivals the systolic pressure (table 6) .
Diabetes predisposes to cardiac failure at all ages in both sexes (table 5) . This is attributed to often associated hypertension and obesity, but diabetes also directly damages the myocardium. Diabetic cardiac failure is not only a product of associated premature coronary disease; structural, functional, and metabolic abnormalities have been found in the diabetic heart that indicate the presence of a diabetic cardiomyopathy.
Although the serum total cholesterol is only weakly related to occurrence of cardiac failure, dyslipidaemia characterised by a high Women total to high density lipoprotein cholesterol ratio is powerfully associated with the occurrence of CHF (fig 8) . It is presumed that the association is mediated by interim promotion of accelerated coronary atherogenesis. Obesity is an important contributor to cardiac failure, particularly in women, both directly and also by promoting hypertension, left ventricular hypertrophy, insulin resistance, and dyslipidaemia. Cigarette smoking is a weak risk factor for cardiac failure in younger men and older women (table 5) .
High risk candidates for cardiac failure can be identified from a multivariate cardiovascular risk profile comprising systolic blood pressure, glucose tolerance, left ventricular hypertrophy on electrocardiogram, blood lipids, vital capacity, heart rate, and cardiac enlargement on x ray film (fig 9) . Evidence of hypertrophy from electrocardiography and x ray films each independently predict occurrence of CHF and patients with both are at substantially greater risk than those with either alone (fig   7) .
Intervention to correct these risk factors before cardiac disease becomes evident would seem to be more effective than later interventions. Optimal prevention should derive from detection and correction of modifiable predisposing factors before extensive myocardial damage occurs. The causes of idiopathic dilated and hypertrophic cardiomyopathy are too ill defined to be preventive except for those due to alcohol and toxins.
Cardiac failure continues to be a main cause of death and disability despite innovations in treatment and more sophisticated diagnostic methods to detect cardiac malfunction. National and Framingham Study secular trend analysis gives no indication of declining morbidity and mortality from CHF despite improved treatment of coronary disease and hypertension. Coronary disease and cardiomyopathy seem to be assuming increasing importance as causes of cardiac failure. A rising prevalence of diabetes can also be expected to assume greater importance. Improvement in survival seems to require earlier detection and correction of impaired systolic and diastolic function and correction of left ventricular hypertrophy. The greatest impact on incidence of CHF and mortality can be achieved by correction of modifiable risk factors such as hypertension, diabetes, dyslipidaemia, left ventricular hypertrophy and obesity. Multivariate assessment of risk of CHF (fig 9) can be used to detect high risk candidates in whom non-invasive studies of ventricular dysfunction can be carried out to detect highly vulnerable people who require urgent and vigorous preventive measures. 
